Shionogi Signs ¥20 Billion License With Oncotherapy Science And Enters Cancer Vaccine Business
This article was originally published in PharmAsia News
Executive Summary
Osaka-based Shionogi signed a licensing agreement with Kawasaki-based biotech venture company Oncotherapy Science and obtained exclusive worldwide rights to develop and market the company's cancer vaccines. Billed as the biggest deal between a Japanese drug maker and a domestic drug discovery venture company, the deal includes a one-time payment, milestone fees and royalties estimated at roughly ¥20 billion. Listed in Tokyo Stock Exchange's Mothers market, Oncotherapy Science specializes in developing cancer vaccines. Shionogi will obtain pre-clinical trial vaccine candidates whose efficacy and develop them in house. (Click here for more - Japanese language